Skip to main content
DNA Labs India

Cancer Targeted Gene Panel: Colon / Colorectal Test

DNA Labs India | ISO 9001:2015 Certified

Cancer Targeted Gene Panel: Colon / Colorectal Test

Short Name: Colorectal Gene Panel

Also known as: Colorectal Cancer Gene Panel Test, Colon Cancer NGS Panel, CRC Targeted Gene Panel, Colorectal Tumor Molecular Profiling

Cancer Targeted Gene Panel: Colon / Colorectal Test test available at DNA Labs India for ₹20,000. Uses Next-Generation Sequencing (NGS), Immunohistochemistry (IHC) on Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block samples. Results in Reports are delivered within 10 working days from sample receipt and quality approval at the laboratory.. Free home collection in 300+ cities across India.

Molecular DiagnosticsUnisexAdults🏠 Home Collection

✍️ Written By

🩺 Medically Reviewed By

Dr Pasupathy Arumugam

Dr Pasupathy Arumugam

Consultant Pathologist · Reg: 21521

Last reviewed: September 7, 2026

Overview

The primary purpose of the Cancer Targeted Gene Panel: Colon/Colorectal Test is to identify actionable genetic mutations in patients with colorectal cancer. The test evaluates the Microsatellite Instability (MSI) Panel, which helps determine eligibility for immunotherapy. KRAS mutation analysis guides the use of anti-EGFR therapies such as cetuximab and panitumumab. BRAF mutation detection is critical for prognosis assessment and consideration of BRAF-targeted therapies. PIK3CA and PTEN evaluations provide additional insight into the PI3K/AKT signaling pathway, which may influence treatment selection and resistance patterns. This comprehensive molecular profiling enables personalized treatment planning, helping oncologists select the most appropriate targeted therapies, immunotherapies, or conventional chemotherapy regimens based on the individual genetic profile of each patient's tumor.

Test Code
263
CPT Code
81445
ICD Code
C18-C20
Price
₹20,000
Sample Type
Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block
Result Time
Reports are delivered within 10 working days from sample receipt and quality approval at the laboratory.
Fasting Required
No
Method
Next-Generation Sequencing (NGS), Immunohistochemistry (IHC)
Step 1

Sample Collection

Duly filled NGS Test Requisition Form (Form 40) is mandatory. Ensure that the treating physician or pathologist has collected and processed the tumor tissue specimen as a formalin-fixed paraffin-embedded (FFPE) block. Confirm that the tissue block contains at least 10% tumor tissue. Provide complete clinical history including cancer stage, prior treatments, and family history of cancer.

Method: Surgical/Biopsy tissue specimen collected by treating physician; shipped at room temperature

Step 2

Laboratory Analysis

The FFPE tissue block is submitted by the treating physician, pathologist, or hospital laboratory. The block must be properly labeled with patient identification details and sealed to prevent contamination. Ship the sample at room temperature. The NGS Test Requisition Form (Form 40) must accompany the sample.

Step 3

Report Delivery

After sample submission, the tissue block undergoes quality assessment at DNA Labs India. DNA is extracted from the FFPE tissue and subjected to next-generation sequencing and immunohistochemical analysis. Results are typically available within 10 working days and delivered via the online portal, email, or WhatsApp.

Timeline: Reports are delivered within 10 working days from sample receipt and quality approval at the laboratory.

Patient Instructions

1
Before the Test:Ensure the NGS Test Requisition Form (Form 40) is completely and accurately filled out. Provide the FFPE tissue block with at least 10% tumor content. Include all relevant clinical information, pathology reports, cancer staging details, and prior treatment history. No fasting is required. Consult your oncologist to confirm the need for this test.
2
During the Test:This is a laboratory-based test performed on the submitted FFPE tissue block. The patient does not need to be present during testing. DNA is extracted from the tissue, and next-generation sequencing is performed to detect mutations in KRAS, BRAF, PIK3CA, PTEN genes. Immunohistochemistry is used to evaluate microsatellite instability status. No invasive procedure is performed at the laboratory.
3
After the Test:After testing is complete, the results are compiled into a comprehensive molecular report that includes mutation status for each gene, MSI classification, and clinical interpretation. The report is made available through the online portal, email, or WhatsApp within 10 working days. Share the report with your oncologist for treatment planning. Genetic counselling may be recommended based on the findings.

About This Test

Who Should Get This Test

The primary purpose of the Cancer Targeted Gene Panel: Colon/Colorectal Test is to identify actionable genetic mutations in patients with colorectal cancer. The test evaluates the Microsatellite Instability (MSI) Panel, which helps determine eligibility for immunotherapy. KRAS mutation analysis guides the use of anti-EGFR therapies such as cetuximab and panitumumab. BRAF mutation detection is critical for prognosis assessment and consideration of BRAF-targeted therapies. PIK3CA and PTEN evaluations provide additional insight into the PI3K/AKT signaling pathway, which may influence treatment selection and resistance patterns. This comprehensive molecular profiling enables personalized treatment planning, helping oncologists select the most appropriate targeted therapies, immunotherapies, or conventional chemotherapy regimens based on the individual genetic profile of each patient's tumor.

How to Prepare

  • Submit a formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue
  • Duly filled NGS Test Requisition Form (Form 40) is mandatory and must accompany the sample
  • Ship the tissue block at room temperature in a secure, sealed container
  • Ensure proper labeling of the tissue block with patient name, ID, and date of collection
  • Include complete clinical details including cancer staging, treatment history, and relevant pathology reports
  • Free home sample collection is available for online bookings across India

Doctor's Notes

Reviewed by — MBBS, MD (Pathology) · Reg. No. 21521

"Molecular profiling of colorectal cancer through targeted gene panels has become an essential part of treatment planning. Identifying mutations in KRAS, BRAF, PIK3CA, and PTEN, along with microsatellite instability status, directly influences the choice between targeted therapies, immunotherapy, and conventional chemotherapy. I recommend this panel for all patients with newly diagnosed or metastatic colorectal cancer to ensure precision-guided treatment decisions and improved clinical outcomes."

Last medically reviewed: September 7, 2026

Test Parameters & Specifications

Sample TypeFormalin-Fixed Paraffin-Embedded (FFPE) Tissue Block
Sample VolumeTissue block must contain at least 10% tumor tissue
ContainerSealed FFPE tissue block container
Collection MethodSurgical/Biopsy tissue specimen collected by treating physician; shipped at room temperature

Sample Stability

FFPE tissue blocks are stable at room temperature for years when properly prepared and stored
Ship samples at room temperature; avoid exposure to extreme heat or moisture
DNA extracted from FFPE samples is stable for the duration of the testing process
Samples should be processed within a reasonable timeframe to ensure optimal DNA quality
Sample Rejection Criteria:
  • Tissue block containing less than 10% tumor tissue
  • Inadequately fixed, severely degraded, or decalcified tissue samples
  • Missing or incomplete NGS Test Requisition Form (Form 40)
  • Unlabeled, mislabeled, or improperly sealed tissue blocks
  • Samples received without proper patient identification or clinical details
  • Non-tumor tissue specimens submitted without prior approval from the laboratory

Understanding Your Results

The Cancer Targeted Gene Panel: Colon/Colorectal Test provides a comprehensive molecular profile of the tumor by identifying mutations in key genes and evaluating microsatellite instability status. Results guide oncologists in selecting personalized treatment strategies, including targeted therapies and immunotherapies. Each parameter is reported as mutation detected (positive) or no mutation detected (wild type), along with the clinical significance of each finding for treatment planning and prognosis assessment.
📊

Indicates deficient mismatch repair (dMMR). MSI-H tumors are associated with better prognosis in early-stage disease and high responsiveness to immune checkpoint inhibitors (e.g., pembrolizumab). Found in approximately 15% of colorectal cancers. May also suggest Lynch syndrome and warrant genetic counselling.

📊

Indicates proficient mismatch repair (pMMR). These tumors are less likely to respond to immunotherapy. Treatment decisions are guided by other molecular markers such as KRAS, BRAF, and PTEN status.

📊

Presence of KRAS mutations (codons 12, 13, 61) indicates resistance to anti-EGFR monoclonal antibodies (cetuximab, panitumumab). These patients should not be treated with anti-EGFR therapy. Alternative chemotherapy regimens or other targeted therapies should be considered.

📊

No KRAS mutation detected. The patient may be eligible for anti-EGFR therapy (cetuximab or panitumumab) in combination with chemotherapy, provided other relevant markers are also favorable.

📊

Associated with poor prognosis and aggressive disease. Patients may benefit from BRAF-targeted combination therapies (e.g., encorafenib plus cetuximab). MSI status should be evaluated concurrently, as MSI-H/BRAF-mutant tumors may respond to immunotherapy.

📊

Activating mutations in PIK3CA may influence response to PI3K pathway inhibitors. Aspirin use has been associated with improved outcomes in PIK3CA-mutant colorectal cancer in some studies. Discuss treatment implications with the oncologist.

📊

Loss of PTEN function leads to activation of the PI3K/AKT pathway and may confer resistance to anti-EGFR therapy. PTEN loss is associated with more aggressive disease and may inform the selection of PI3K/AKT/mTOR pathway inhibitors.

⚠️ When to Consult a Doctor:

Consult your oncologist if you have been diagnosed with colorectal cancer and require molecular profiling for treatment planning. This test is also recommended if you have a strong family history of colorectal cancer, if your cancer has recurred or progressed despite treatment, or if your doctor needs to evaluate eligibility for targeted therapy or immunotherapy. If you experience symptoms such as persistent changes in bowel habits, blood in the stool, unexplained weight loss, or abdominal pain, consult a physician immediately for further evaluation.

Limitations

  • ⚠This test is not a screening tool for colorectal cancer; it requires an existing tumor tissue specimen
  • ⚠The panel evaluates specific genes and may not detect all possible genetic alterations in colorectal cancer
  • ⚠Results should always be interpreted in conjunction with clinical findings, histopathology, and other diagnostic information
  • ⚠Germline (inherited) mutations may not be reliably distinguished from somatic (acquired) mutations without additional germline testing
  • ⚠Novel or rare variants of uncertain significance (VUS) may be identified, requiring further clinical correlation
  • ⚠Epigenetic changes such as promoter methylation are not fully assessed by this panel unless specifically included

Risks & Considerations

  • ●This test requires a pre-collected tissue specimen and poses no direct physical risk to the patient during the testing process
  • ●Identification of pathogenic mutations may have psychological and emotional impact; genetic counselling is recommended
  • ●Results indicating hereditary cancer predisposition may have implications for family members who may also require testing
  • ●Variants of uncertain significance (VUS) may cause anxiety without providing clear clinical guidance

Interfering Factors

  • ●Insufficient tumor content in the tissue block (less than 10%)
  • ●Degraded or poorly preserved DNA from improper tissue fixation or storage
  • ●Inadequate or prolonged formalin fixation affecting DNA quality
  • ●Presence of necrotic tissue or extensive inflammation masking tumor cells
  • ●Contamination during sample collection, transport, or processing

Compare With Similar Tests

TestCancer Targeted Gene Panel: Colon / Colorectal TestCEA (Carcinoembryonic Antigen) Blood TestColonoscopy with BiopsyFecal Immunochemical Test (FIT)Liquid Biopsy (Circulating Tumor DNA)
ComparisonCancer Targeted Gene Panel: Colon / Colorectal TestCEA is a tumor marker measured in blood used for monitoring treatment response and recurrence. The Cancer Targeted Gene Panel analyzes DNA mutations at the genetic level to guide targeted therapy selection. They serve complementary but distinct clinical purposes.Colonoscopy visually examines the colon and collects tissue samples. The Gene Panel test analyzes the collected tumor tissue for specific genetic mutations. Colonoscopy is a diagnostic and screening tool, while the gene panel guides treatment decisions after diagnosis.FIT is a non-invasive screening test that detects hidden blood in stool. It does not provide genetic information. The Cancer Targeted Gene Panel requires tumor tissue and provides detailed molecular profiling for treatment planning.Liquid biopsy detects tumor-derived DNA fragments in blood and is useful when tissue biopsy is not feasible. The FFPE-based gene panel analyzes tumor tissue directly and may provide more comprehensive mutational profiling. Both serve important roles in treatment monitoring and selection.

Frequently Asked Questions

What is the Cancer Targeted Gene Panel: Colon/Colorectal Test?
The Cancer Targeted Gene Panel: Colon/Colorectal Test is a comprehensive molecular diagnostic test that uses next-generation sequencing (NGS) and immunohistochemistry to analyze multiple genes (KRAS, BRAF, PIK3CA, PTEN) and microsatellite instability status in colorectal cancer tumor tissue. It helps guide personalized treatment decisions including targeted therapy and immunotherapy.
Who should take this test?
This test is recommended for patients diagnosed with colorectal cancer who need molecular profiling for treatment planning, patients with metastatic or advanced-stage disease, individuals with a family history of colorectal cancer, and patients being considered for targeted therapy or immunotherapy. Your oncologist will advise if this test is appropriate for your clinical situation.
What sample is required for this test?
The test requires a formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue. The tissue block is typically collected during a biopsy or surgical procedure performed by your treating physician. A duly filled NGS Test Requisition Form (Form 40) must accompany the sample.
How much does the Cancer Targeted Gene Panel: Colon/Colorectal Test cost?
The test costs INR 20,000 (twenty thousand rupees). This price includes next-generation sequencing analysis, immunohistochemistry, sample processing, and report delivery. Free home sample collection is available for online bookings across India.
How long does it take to get the test results?
Results are typically available within 10 working days from the date the sample is received and quality-approved at the laboratory. Reports are delivered through the online portal, email, or WhatsApp.
What genes are analyzed in this panel?
The panel analyzes the following genes and markers: Microsatellite Instability (MSI) Panel, KRAS, BRAF, PIK3CA, and PTEN. These are key biomarkers for colorectal cancer that influence treatment selection, including eligibility for anti-EGFR therapy, immunotherapy, and targeted pathway inhibitors.
What is microsatellite instability (MSI) and why is it important?
Microsatellite instability (MSI) refers to changes in the length of repetitive DNA sequences caused by defects in the DNA mismatch repair system. MSI-High (MSI-H) tumors are more likely to respond to immunotherapy such as pembrolizumab. MSI status also helps identify patients who may have Lynch syndrome, an inherited condition that increases cancer risk.
Is this test the same as a colonoscopy?
No. A colonoscopy is an endoscopic procedure that visually examines the colon for polyps or cancer and collects tissue samples. The Cancer Targeted Gene Panel analyzes the collected tumor tissue at the molecular level to identify specific genetic mutations. They are complementary tests used at different stages of diagnosis and treatment planning.
Can this test detect all types of colorectal cancer mutations?
This test is a targeted panel that analyzes specific, well-characterized genes associated with colorectal cancer. While it covers the most clinically actionable mutations, it may not detect every possible genetic alteration. If more comprehensive testing is needed, your oncologist may recommend whole-exome sequencing or expanded genomic profiling.
Is home sample collection available for this test?
Yes, DNA Labs India offers free home sample collection for online bookings across India. However, since this test requires a tissue block (typically collected during biopsy or surgery), the sample is usually submitted by the treating hospital or pathology laboratory. You may contact DNA Labs India for coordination and logistics support.
How should I prepare for this test?
No special preparation such as fasting is required. Ensure that the NGS Test Requisition Form (Form 40) is completely filled out with all relevant clinical information. Provide the FFPE tissue block with adequate tumor content along with pathology reports and cancer staging details. Your oncologist's office will typically coordinate the sample submission.
What happens if mutations are detected in the test results?
If actionable mutations are detected, your oncologist will use this information to select the most appropriate treatment strategy. For example, KRAS wild-type results may allow anti-EGFR therapy, MSI-H tumors may qualify for immunotherapy, and BRAF mutations may guide the use of BRAF-targeted therapies. A comprehensive report with clinical interpretation is provided to guide these decisions.
Worried about the process? Our certified phlebotomists collect thousands of samples every month across India. The process takes under 5 minutes and is virtually painless. Questions? Message us on WhatsApp — we're here 7 days a week.

Related Tests

B-Cell Rearrangement Detection Test

₹22,000

Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test

₹20,000

Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test

₹6,000

OncoPro NCCN Lung Cancer Panel with PD-L1 Test

₹140,400

Acute Myeloid Leukemia (AML) Cytogenetics Panel Test

₹23,000

AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test

₹6,000
For Hospitals & Clinics

Reference Laboratory Services

We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.

LIMS Integration

Your Data Privacy

Your medical data is protected under Indian law.

✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.

✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.

Book Your Test

Enter your details and we'll connect you within 15 minutes.

🧬

Quick Connect

Enter your mobile number and we’ll connect you with the team.

+91

✅ Connecting you now...

🔒 Your number is used to respond to this request.